Cardiol Therapeutics (CRDL) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 24.5% versus a loss of 22.1%. Over five years, CRDL leads with a -66.4% price change compared with -74.1% for IPHA. Innate Pharma S.A. is the larger company by market cap ($164.2 million vs $157.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | IPHA |
|---|---|---|
| Share price | $1.30 | $1.47 |
| Market cap | $157.36M | $164.20M |
| 1-day change | -1.89% | -3.21% |
| YTD return | +38.36% | -13.14% |
| 1-year return | +24.53% | -22.05% |
| 5-year return | -66.41% | -74.11% |
| EPS (TTM) | $-0.25 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $2.71 |
| 52-week low | $0.88 | $1.17 |
| Distance from 52-week high | -44.66% | -45.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +545.56% | +353.74% |
| Average volume | 1.44M | 156.71K |
| Shares outstanding | 121.51M | 111.70M |
| Employees | 18 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed IPHA by 46.6 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
CRDL vs IPHA FAQ
Which is bigger, Cardiol Therapeutics or Innate Pharma S.A.?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $164.20M compared with $157.36M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or IPHA?
CRDL returned +24.53% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.